Genetic polymorphism of CYP2D6 in patients with systemic lupus erythematosus and systemic sclerosis

References

• Ledesma, M. C., and J. A. G. Agundez. 2005. Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication. Clin. Chem. 51: 939–943
   PubMed Web of Science ®Google Scholar
• Lopez, M., J. Guerrero, H. Jung-Cook, and M. E. Alonso. 2005. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. Eur. J. Clin. Pharmacol. 61: 749–754
   PubMed Web of Science ®Google Scholar
• Wong, J. Y., E. S. Seah, and E. J. Lee. 2000. Pharmacogenetics: the molecular genetics of CYP2D6 dependent drug metabolism. Ann. Acad. Med. Singapore. 29: 401–406
   PubMedGoogle Scholar
• The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Available from: www.cypalleles.ki.se
   Google Scholar
• Skrętkowicz, J., and M. Rychlik-Sych. 2008. [Polimorphism of cytochrome P-450]. Farm. Pol. 64: 61–72
   Google Scholar
• Ingelman-Sundberg, M. 2004. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends. Pharmacol. Sci. 25: 193–200
   PubMed Web of Science ®Google Scholar
• Nambiar, M. P., Y.T. Juang, S. Krishanan, and G. C. Tsocos. 2004. Dissecting the molecular mechanisms of TCR ζ chain downregulation and T cell signaling abnormalities in human systemic lupus erythematosus. Int. Rev. Immunol. 23: 245–263
   PubMed Web of Science ®Google Scholar
• Horiuchi, T., M. Washio, Ch. Kiyohara, et al. Kyushu Sapporo SLE Study Group. 2009. Combination of TNF-RII, CYP1A1 and GSTM1 polymorphisms and the risk of Japanese SLE: findings from the KYSS study. Rheumatology 48: 1045–1049
   PubMed Web of Science ®Google Scholar
• Valentini, G. 2003. The assessment of the patent with systemic sclerosis. Autoimmun. Rev. 2: 37–376
   Web of Science ®Google Scholar
• Tikly, M., S. E. Marshall, N. A. Haldar, et al. 2004. Oxygen free radical scavenger enzyme polymorphisms in systemic sclerosis. Free. Radic. Biol. Med. 36: 1403–1407
   PubMed Web of Science ®Google Scholar
• Fonesca, C., G. E. Lindahl, M. Ponticos, et al. 2007. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N. Engl. J. Med. 357: 1210–1220
   PubMed Web of Science ®Google Scholar
• O'Reilly, S. 2015. miRNA-29a in systemic sclerosis: a valid target. Autoimmunity 3: 1–2
   Google Scholar
• Raman, K., and C. Mohan. 2003. Genetic underpinnings of autoimmunity-lessons from studies in arthritis, diabetes, lupus and multiple sclerosis. Curr. Opin. Immunol. 15: 651–659
   PubMed Web of Science ®Google Scholar
• Kim, R., M. Emi, and K. Tanabe. 2006. Cancer immunosupresion and autoimmune disease: beyond immunosuppressive networks for tumor immunity. Immunology. 119: 254–264
   PubMed Web of Science ®Google Scholar
• Li, M. O., Y. Y. Wan, S. Sanjabi, et al. 2006. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 24: 99–146
   PubMed Web of Science ®Google Scholar
• Pontillo, A., E. C. Reis, B. L. Liphaus, et al. 2015. Inflammasome polymorphisms in juvenile systemic lupus erythematosus. Autoimmunity 16: 1–4
   Google Scholar
• Silver, I., M. P. Heyes, J. C. Maize, et al. 1990. Scleroderma, fasciitis and eosinophilia associated with the ingestion of tryptophan. N. Engl. J. Med. 322: 874–881
   PubMed Web of Science ®Google Scholar
• D’Cruz, D. 2000. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol. Lett. 112–113: 421–432
   PubMed Web of Science ®Google Scholar
• Smith, C. A., A. C. Gough, P. N. Leigh, et al. 1992. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinsons disease. Lancet 6: 1375–1377
   Google Scholar
• Sekigawa, I., T. Naito, K. Hira, et al. 2004. Possible mechanisms of gender bias in SLE: a new hypothesis involving a comparison of SLE with atopy. Lupus 13: 217–222
   PubMed Web of Science ®Google Scholar
• Wojtczak, A., M. Rychlik-Sych, E. Krochmalska-Ulacha, and J. Skrętkowicz. 2007. CYP2D6 phenotyping with dextromethorphan. Pharmacol. Rep. 59: 734–738
   PubMed Web of Science ®Google Scholar
• Sistonen, J., S. Fuselli, A. Levo, A. and Sajantila. 2005. CYP2D6 genotyping by a multiplex primer extension reaction. Clin. Chem. 51: 1291–1295
   PubMed Web of Science ®Google Scholar
• Mann, A., S. L. Miksys, A. Gaedigk, et al. 2012. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson’s disease patients. Neurobiol. Aging 33: 2160–2171
   PubMed Web of Science ®Google Scholar
• Singh, M., V. K. Khanna, R. Shukla, and D. Parmar. 2010. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease. Dis. Markers 28: 87–93
   PubMed Web of Science ®Google Scholar
• Sachse, C., G. Smith, M. J. Wilkie, et al. Colorectal Cancer Study Group. 2002. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23: 1839–1849
   PubMed Web of Science ®Google Scholar
• Nimura, Y., S. Yokoyama, M. Fujimori, et al. 1997. Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer 80: 852–857
   PubMed Web of Science ®Google Scholar
• Rychlik-Sych, M., J. Skrętkowicz, B. Gawrońska-Szklarz, et al. 2006. Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol. Rep. 58: 22–29
   PubMed Web of Science ®Google Scholar
• Skrętkowicz, K., J. Skrętkowicz, B. Gawrońska-Szklarz, et al. 2005. Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis. Eur. J. Clin. Pharmacol. 60: 773–778
   PubMed Web of Science ®Google Scholar
• Skrętkowicz, J., M. Barańska, and M. Rychlik-Sych. 2009. Genetic polymorphisms of CYP2D6 oxidation in patients with systemic sclerosis. Eur. J. Clin. Pharmacol. 65: 971–976
   PubMed Web of Science ®Google Scholar
• Sabbagh, N., D. Marez, V. Queyrel, et al. 1998. Genetic analysis of cytochrome P450 CYP2D6 polymorphism in patients with systemic lupus erythematosus. Pharmacogenetics 8: 191–194
   PubMedGoogle Scholar
• Kortunay, S., A. Bozkurt, L. Bathum, et al. 1999. CYP2D6 polymorphism in systemic lupus erythematosus patients. Eur. J. Clin. Pharmacol. 55: 21–25
   PubMed Web of Science ®Google Scholar
• Skrętkowicz, J., M. Barańska, A. Kaczorowska, and M. Rychlik-Sych. 2011. Genetic polymorphisms of CYP2D6 oxidation in patients with systemic lupus erythematosus. Arch. Med. Sci. 5: 864–869
   Google Scholar
• Von Schmiedeberg, S., E. Fritsche, A. C. Ronnau, et al. 1999. Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv. Exp. Med. Biol. 455: 147–152
   PubMed Web of Science ®Google Scholar
• Yen, J.H., Ch.-J. Chen, W.-Ch. Tsai, et al. 2003. Cytochrome P450 and manganese superoxide dismutase genes polymorphisms in lupus systemic erythematosus. Immunol. Lett. 90: 19–24
   PubMed Web of Science ®Google Scholar
• Kortunay, S., A. Bozkurt, L. Bathum, et al. 1999. CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus. Ann. Rheum. Dis. 58: 182–185
   PubMed Web of Science ®Google Scholar
• Povey, A., M. J. Guppy, M. Wood, et al. 2001. Cytochrome P2 polymorphism and susceptibility to scleroderma following exposure to organic solvents. Arthritis. Rheum. 44: 662–665
   PubMedGoogle Scholar
• Barańska, M., B. Dziankowska-Bartkowiak, E. Waszczykowska, et al. 2012. Significance of genetic polymorphism of CYP2D6 in the pathogenesis of systemic sclerosis. Pharmacol. Rep. 64: 336–342
   PubMed Web of Science ®Google Scholar
• Niewiński, P., K. Orzechowska-Juzwenko, M. Hurkacz, et al. 2002. CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population. Eur. J. Clin. Pharmacol. 58: 533–535
   PubMed Web of Science ®Google Scholar